Furosemide has historically been the primary loop diuretic in heart failure (HF) patients despite data suggesting potential advantages with torsemide. We used the Duke Echocardiography Lab Database to investigate patients admitted with HF to Duke Hospital from 2000-2010 who were discharged on either torsemide or furosemide. We described baseline characteristics based on discharge diuretic and assessed the relationship with all-cause mortality through 5 years. Of 4,580 patients, 86% (n=3,955) received furosemide and 14% (n=625) received torsemide.
INTRODUCTION
Loop diuretics including furosemide and torsemide are prescribed for the treatment of symptomatic heart failure (HF) 1, 2 . Current HF guidelines indicate that loop diuretics are a central treatment for the management of volume overload 3 . Compared with furosemide, torsemide has increased bioavailability and a longer half-life 4 , yet furosemide remains the most commonly used loop diuretic 5 . Torsemide also has beneficial effects on myocardial fibrosis, the neurohormonal axis, and ventricular structure [6] [7] [8] [9] [10] [11] . Several small studies of torsemide vs. furosemide [12] [13] [14] and a meta-analysis 15 suggest improved clinical outcomes with torsemide.
These previous studies had modest sample sizes and were conducted prior to the use of contemporary HF therapies. In order to investigate the role of torsemide in current clinical practice, we assessed loop diuretics use at a large, tertiary care hospital over the past decade and evaluated the association with baseline characteristics and post-discharge outcomes.
METHODS
We assessed patients admitted to Duke University Medical Center (DUMC) with a primary discharge diagnosis of HF between 2000 through 2010 that were included in the Duke . The Duke Institutional Review Board approved this study.
The primary outcome for the present analysis was all-cause mortality through 5 years post-discharge. Secondary outcomes were 30-day all-cause mortality or hospitalization and 30-day hospitalization. Rehospitalization evaluation was limited to the Duke Health system. We were also interested in identifying clinical factors associated with patients being discharged on torsemide as compared with furosemide.
Demographics, medical history, laboratory findings, and therapies were summarized as frequencies and percentages for categorical variables and by the medians and 25th and 75th percentiles for continuous variables in patients discharged on either torsemide or furosemide.
Baseline characteristics were compared using the Wilcoxon rank sum test for continuous variables, and Pearson chi-square tests for categorical variables as appropriate. We generated a multivariable logistic regression model to determine admission variables associated with discharge torsemide use (over furosemide) using backward selection with a p-value of 0.10 to stay in the model. Candidate variables were those included in the baseline characteristics table (Table 1) . Year of HF hospitalization was included as an adjustment variable in all models. We assessed linearity of continuous variables and fit interpretable linear splines when necessary.
Because the choice of diuretic at discharge was not randomized, a multivariable model was used to estimate propensity scores -individual probabilities of torsemide use at discharge.
Logistic (for 30-day endpoints) and Cox proportional hazards regression (for mortality through 5 years) models assessed the association between discharge loop diuretics and clinical outcomes using inverse probability weighting (IPW). In brief, patients are weighted by the inverse of their estimated probability of diuretic actually received. Covariate balance under IPW was assessed using standardized differences 18 . A covariate-adjusted model was also evaluated to assess to association of torsemide use with clinical endpoints. We assessed linearity and proportional hazards assumptions for adjustment covariates and discharge medications and applied appropriate transformations as needed. No violations were detected for loop diuretics. Hazard ratios (HRs) for long-term mortality and odds ratios (ORs) for other endpoints were calculated with corresponding 95% confidence intervals (CIs) relative to discharge diuretic. Event rate curves were shown using unadjusted Kaplan-Meier estimates. Statistical significance was assessed using 2-sided P values. A P value <0.05 was considered statistically significant. All statistical computations were generated using SAS version 9.2 or higher (SAS Institute Inc., Cary, NC).
RESULTS
We identified 7,442 unique patients with a HF admission to DUMC between Jan 1, 2000
and Dec 31, 2010 who were discharged alive. Of these, 4580 patients had an echocardiogram prior to discharge and were discharged on either torsemide or furosemide. Of 4,580 patients, 86% (n=3,955) received furosemide and 14% (n=625) received torsemide. Factors associated with torsemide use at discharge in a multivariable model are presented in Table 2 . Clinical factors independently associated with torsemide use were younger age, female sex, higher EF, renal dysfunction, RV dilatation and tricuspid regurgitation. 
DISCUSSION
In a large single center HF cohort, we found that furosemide was the primary loop Despite preclinical and clinical data suggesting beneficial pharmacologic and diseasespecific benefits with torsemide over furosemide [6] [7] [8] [9] [10] [11] , we did not demonstrate improved outcomes with torsemide. There are several potential explanations for these findings. First, despite multiple adjustment models, other measured and unmeasured variables may have influenced these results. Outside the context of a randomized clinical trial, the effect of torsemide as compared with furosemide cannot be established. Alternatively, while earlier studies suggested anti-fibrotic effects with torsemide 10, 19, 20 , it remains unclear whether these effects translate into clinically meaningful benefits for patients. Loop diuretics have not previously been shown to be associated with improved clinical outcomes in prospective evaluations 3 . Third, previous studies suggesting an association between torsemide and outcomes were conducted in the chronic HF populations 13 rather than those recently hospitalized with HF. There may be important clinical differences between the chronic stable HF population and those with acute HF with respect to the benefit of different therapies 21, 22 . Furthermore, data are not available for this cohort regarding whether or not there was equivalent dosing in torsemide vs. furosemide treated patients.
With a sample size of 4,580 patients, this is largest analysis to date comparing torsemide to furosemide use in the HF population. When considering risk adjustments, our analysis was inclusive of echocardiographic data allowing for adjustments based on more objective variables as compared to prior analyses that incorporated subjective measures such as NYHA class. Furthermore, prior studies of mortality and hospitalization comparing torsemide vs. furosemide-treated patients averaged <1 year of follow-up, while our analysis provides data on long-term mortality with a follow-up interval of 5 years.
The dramatic increase in the use of torsemide over the past several years highlights the importance of obtaining prospective data comparing these 2 loop diuretics. There is an unmet need to empirically test the potential benefits of torsemide that have been identified in earlier studies 10, 19, 20 . At present, the preferential use of furosemide is likely due to furosemide being first to market in 1966 compared with torsemide which was FDA-approved in 1993 and became generic in 2002. We observed that the use of torsemide at our institution began to increase several years later in [2005] [2006] . There is no preferred diuretic at our institution and diuretic choice is left to the discretion of the treating provider. Clinicians tend to have greater experience with furosemide and it has historically been less expensive. These 2 drugs now have comparable costs. Studies that were conducted even prior to the widespread availability of generic torsemide 23 suggest that despite a previously higher acquisition cost, torsemide may be associated with a reduction in total cost per patient. Randomized trial data comparing loop diuretic strategies would provide an opportunity to improve HF management and reduce health care expenditures with currently available therapies.
There are several limitations to our study. First, this was a retrospective analysis from a single tertiary referral center. The analysis cohort required that patients had an echocardiogram during hospitalization. We included patients with both preserved EF and reduced EF. The generalizability of these results to HF populations with different baseline characteristics is unclear. Data were not consistently available regarding post-discharge loop diuretic adjustments. Thus, there is the potential for crossover between furosemide and torsemide which could confound these results. The analysis population was not a new-user design given the routine use of loop diuretics in clinical practice in order to manage volume overload.
Rehospitalization data were limited to those within the Duke Health System. These data may provide the rationale for an appropriately powered clinical trial of the comparative-effectiveness of furosemide vs. torsemide in HF patients.
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